BRIEF—Jeito I now largest European fund dedicated to life sciences sector

Paris, France-based Jeito Capital, a rapidly growing, new, independent private equity firm dedicated to biotech and biopharma, today announced the final closing of its first fund, Jeito I, at 534 million euros ($630 million), exceeding its original target of 500 million euros.

Jeito I is the largest European fund dedicated to supporting companies in the life sciences sector.

Jeito Capital is building a strong and diversified portfolio of biotech and biopharma companies primarily based in Europe with global reach, focused on the treatment of life-threatening diseases. Jeito’s unique investment model provides support to entrepreneurs by a multi-talented team of experts integrated in the investment team across the entire drug development value chain, from translational science to market access and commercialization, providing significant capital in continuity, up to 80 million euros ($100 million) in a single company.

Jeito I investments to date include French-based SparingVision and InnoSkel, in the fields of genomic ophthalmology and rare skeletal disorders, respectively, Dutch biotech Neogene Therapeutics in solid tumors, UK-based Pulmocide in severe respiratory diseases, and Swiss-French Alentis Therapeutics in fibrosis and related cancers.